Hsbc Holdings PLC Has $1.71 Million Stock Holdings in Abivax SA Sponsored ADR $ABVX

Hsbc Holdings PLC increased its holdings in shares of Abivax SA Sponsored ADR (NASDAQ:ABVX) by 335.9% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 15,426 shares of the company’s stock after buying an additional 11,887 shares during the quarter. Hsbc Holdings PLC’s holdings in Abivax were worth $1,712,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently bought and sold shares of the company. UBS Group AG boosted its position in Abivax by 2,561.0% during the 3rd quarter. UBS Group AG now owns 4,461,262 shares of the company’s stock worth $378,761,000 after acquiring an additional 4,293,606 shares during the period. Morgan Stanley increased its holdings in shares of Abivax by 114.3% in the 4th quarter. Morgan Stanley now owns 3,151,994 shares of the company’s stock valued at $425,062,000 after purchasing an additional 1,681,277 shares during the period. Paradigm Biocapital Advisors LP purchased a new stake in shares of Abivax in the third quarter worth approximately $132,800,000. TCG Crossover Management LLC lifted its position in shares of Abivax by 17.4% in the third quarter. TCG Crossover Management LLC now owns 7,111,596 shares of the company’s stock worth $603,774,000 after purchasing an additional 1,055,000 shares in the last quarter. Finally, Westfield Capital Management Co. LP acquired a new stake in shares of Abivax during the fourth quarter worth approximately $136,199,000. 47.91% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

ABVX has been the topic of a number of research analyst reports. Wall Street Zen raised shares of Abivax from a “sell” rating to a “hold” rating in a research report on Saturday, May 23rd. Weiss Ratings reissued a “sell (d-)” rating on shares of Abivax in a research note on Friday, July 17th. Leerink Partners boosted their price target on shares of Abivax from $140.00 to $148.00 and gave the company an “outperform” rating in a report on Tuesday, June 30th. HC Wainwright reaffirmed a “buy” rating on shares of Abivax in a research note on Tuesday, June 30th. Finally, Oddo Bhf reiterated an “outperform” rating on shares of Abivax in a report on Thursday, April 9th. Thirteen equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Abivax presently has an average rating of “Moderate Buy” and a consensus price target of $156.50.

Abivax Price Performance

Shares of ABVX opened at $125.70 on Monday. The company’s fifty day moving average is $117.99 and its 200-day moving average is $118.22. Abivax SA Sponsored ADR has a 12 month low of $65.67 and a 12 month high of $148.83. The firm has a market cap of $10.97 billion, a price-to-earnings ratio of -24.13 and a beta of 0.87.

Abivax (NASDAQ:ABVX) last released its quarterly earnings data on Friday, May 22nd. The company reported ($0.71) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.94) by $0.23. The business had revenue of $1.56 million during the quarter, compared to analyst estimates of $0.40 million. As a group, research analysts predict that Abivax SA Sponsored ADR will post -3.4 earnings per share for the current fiscal year.

Abivax Company Profile

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.